Adaptilens is developing an accommodating intraocular lens (IOL) that adapts to the patient's surroundings, aiming to replicate the human lens as closely as possible.

Adaptilens

Adaptilens is the only IOL that imitates the human eye’s natural lens. We are a team of ophthalmologists, cataract specialists, scientists, and engineers with a singular focus on improving the vision and quality of life of cataract patients. We are developing an accommodating IOL with novel polymers to give patients the ability to focus not just on a single distance but on objects near, far, and in between--without the help of glasses or contact lenses. To stay updated as our life-changing lens technology develops, follow us here or sign up for updates here: https://adaptilens.com/contact/

MassChallenge

Pillar VC

Accanto Partners

MassChallenge, one of Adaptilens’s earliest supporters, connects with CEO Liane Clamen, MD for an update. Check out the article below! 

https://lnkd.in/gCB9PNyx

Adaptilens Founder and CEO, Liane Clamen, MD, was honored to lead a roundtable discussion at a Harvard Innovation Labs' forum last week.

This week, the Boston Business Journal featured Dr. Liane Clamen, CEO of Adaptilens, highlighting her remarkable accomplishments in developing a best-in-class intraocular lens.

Adaptilens Founder and CEO Dr. Liane Clamen was honored to be invited to give a presentation on Adaptilens at the International Society of Presbyopia conference in Vienna. Adaptilens’ game-changing Accommodating Intraocular Lens will improve the quality of life of millions of people. #IOL #Ophthalmolgy #innovation

Adaptilens is proud to announce our Series A Financing of $17.5M led by Perceptive Advisors (Perceptive Xontogeny Venture Funds) with participation by Pillar VC, 380 Cap, and Accanto Partners. Together we are transforming the standard of care for cataract surgery.
https://lnkd.in/e7h86cha

Adaptilens CEO, Dr. Liane Clamen, will be co-hosting the 2023 Founder-led Biotech Tour! RSVP below to join her and other inspirational founders in Boston on November 7.

COM:ADAPTILENS

Adaptilens

Financials Not Available